| Literature DB >> 25276177 |
Parvaneh Mirabi1, Seideh Hanieh Alamolhoda2, Seddigheh Esmaeilzadeh1, Faraz Mojab3.
Abstract
Conventional treatment for primary dysmenorrhoea has a failure rate of 20% to 25% and may be contraindicated or not tolerated by some women. Herbal medicine may be a suitable alternative. To determine the efficacy and safety of Iranian herbal medicine for primary dysmenorrhea when compared with placebo, no treatment, and other treatment. Electronic searches of the Cochrane Menstrual Disorders and Dysmenorrhoea Group Register of controlled trials, Scopus, Google Scholar, Medline, Pubmed were performed to identify relevant randomized controlled trials (RCTs). The study abstraction and quality assessment of all studies were undertaken following the detailed descriptions of these categories as described in the JADAD Criteria for Systematic Reviews of Interventions. 25 RCTs involving a total of women were included in the review. The review found promising evidence in the form of RCTs for the use of herbal medicine in the treatment of primary dysmenorrhoea compared with pharmacological treatment. However, the results were limited by methodological flaws. Further rigorous no penetrating placebo-controlled RCTs are warranted. The review found promising evidence supporting the use of herbal medicine for primary dysmenorrhoea; however, results are limited by the poor methodological quality of the included trials.Entities:
Keywords: Herbal medicine; JADAD Criteria; Primary dysmenorrhea; Randomized controlled trials
Year: 2014 PMID: 25276177 PMCID: PMC4177637
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Clinical trials have been conducted on the impact of Foeniculum vulgare on primary dysmenorrheal (PD).
| Jadad score | Side effects and possible reaction | Results | Measure | Participants | Control group | Experimental group | method | Authors (year) | Ref |
|---|---|---|---|---|---|---|---|---|---|
| Cannot be calculated | Not mentioned | The pain Reduced by | VAS | 60 students | 1st cycle as control, cycles 2 and 3 | A clinical trial (before - after) | Yazdani | 16 | |
| Cannot be calculated | Increased bleeding in 1 case | The pain reduced by | VAS | 30 students 15-24 years old with PD (moderate and severe) | 1st cycle without drug, 2nd cycle Mefenamic Acid 250mg/QID, 3rd cycle 25 drops | A clinical trial witnessed 3 cycles | Namvar-Jahromi | 13 | |
| 5 | Three groups did not differ | more reduction in pain intensity with | VRS | 60 single female students 17-25 years old | placebo |
| A double-blind, randomized clinical trial, 3 cycle | Khorshidi | 11 |
| 5 | Uncomplicated | Reduction pain in | VAS | 130 single female students 17-25 years old who experienced | placebo |
| A blind, randomized clinical trial, 2 cycle | Tork-zahrani | 10 |
| 4 | Uncomplicated | The pain reduced by | Questionnaire and | 120 single students 17-25 years old who experienced | Mefenamic acid 250 mg/QID and placebo (drop) |
| A blind, randomized clinical trial, 2 cycle | Nazarpoor | 15 |
| 4 | Uncomplicated | not difference between the 2 groups | VMSS | 110 female students 13 years and older | 1st group 30 drops | A blind, randomized clinical trial, 1 cycle before -2 cycles afte | Modarres-nejad | 14 | |
| 5 | Uncomplicated | The pain reduced by | VAS | 60 single students 18-25 years old who experienced | placebo | 30 drops | double-blind, randomized, placebo controlled | Delaram | 12 |
| 5 | Uncomplicated | Mean pain scores were similar between the 2 groups before the inter- vention, pain intensity decreased in 2 groups, but this reduction in | VAS | 60 single students 18-25 years old who experienced | A group, 30 drop | A clinica | Delaram | 57 |
Clinical trials have been conducted on the impact of other herbs on primary dysmenorrheal (PD).
|
|
|
|
|
|
|
|
|
|
| |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5 | Uncomplicated | Herbal extract was more effective than mefenamic acid in pain reduction | VAS | 180 students 18-27 years old | placebo | One group 500 mg/TID Menstrugol® (saffron, celery and aniseed) for first 3 days of menstruation, another group Mefenamic acid 250 mg/TID | double-blind, randomized, placebo controlled | Khodakarami | 23 | |||||||||
| 4 | Uncomplicated | There was no difference between the two groups. | VAS | 161 students 17-30 years old | Placebo | Menstrugol® (saffron, celery and aniseed)/TID for first 3 days of menstruation, another group Mefenamic acid 250 mg/ TID | double-blind, randomized, placebo controlled trial, 3 cycles | Khodayari (2004) | 24 | |||||||||
| 4 | Two patients were excluded due to nausea. | 70 | VAS | 60 students with moderate or severe dysmenorrhea | placebo 40 drops daily for 3 months from the 1st day of menstruation | Vitagnus® ( | double-blind, randomized, placebo controlled trial, 3 cycles | Shahhosseini | 53 | |||||||||
| 5 | Uncomplicated | There was no difference between the 2 groups. | VMSS | 150 students | One group Mefenamic acid 250 mg/QID, another group Ibuprofen 400 mg/QID | 250 mg ginger/QID for 3 days | double-blind, randomized, placebo controlled trial, 3 cycles | Ozgoli | 18 | |||||||||
| 4 | Uncomplicated | Reduction the severity of dysmenorrhea and signs and pain killer and menstrual bleeding | VAS | 72 single female students 18-26 years old with moderate and sever PD | Baby oil | A topical lotion Menastil daily maximum of 3 doses in the first 2 days of menstrual cycles within 2 | double-blind, randomized, placebo controlled trial, 2 cycles | Kariman | 21 | |||||||||
| 5 | Uncomplicated | Reduction the severity of dysmenorrhea in valerian group than placebo. The total scores of the systemic manifestations decreased after | VAS | 100 students 18-24 years | Placebo (starch) 3 days beginning at the onset of menstruation | 250 mg valerian root/TID for 3 days beginning at the onset of menstruation, for 2 consecutive menstrual cycles | randomized clinical trial | Mirabi | 32 | |||||||||
| 4 | Not mentioned |
| VAS | 108 students 18-25 years old with dysmenorrhea (moderate or severe) | Placebo | One group 25 drop | double-blind, randomized, placebo controlled trial, 3 cycles | Irvani | 46 | |||||||||
| 3 | Uncomplicated | There was no difference between the 2 groups. | Questionnaire, | 100 single female students 18-22 years old who experienced moderate–severe dysmenorrhea. |
| 1st cycle without drug, for 2nd cycle 40 drops | Randomized clinical trial, | Amoyi-rokn abaad | 51 | |||||||||
| 5 | Uncomplicated | Reduction in pain compared to placebo group, cinnamon | Questionnaire | 47 single female students 18-30 years old who experienced | Placebo | 5 capsules 420 mg cinnamon for first 3 days of menstruation in 2 consecutive cycles | double-blind, randomized, placebo controlled trial, 2 cycles | Akhavan-amjadi | 37 | |||||||||
| Cannot be calculated | Uncomplicated | During the time of dysmenorea and pain Intensity after consumption | VAS and | 50 single female students 18-25 years old |
| Clinical trial, 2 cycles | Mirabi | 42 | ||||||||||
| 4 | Uncomplicated | There was no difference between the 2 groups. | Questionnaire and VAS | 102 students | 1st group valerian 250 mg within 2 to 3 days of menstruation cycles, and the 2nd group 250 mg Mefenamic acid | Randomized clinical trial | Jenabi | 27 | ||||||||||
| 5 | Uncomplicated | The duration and severity of primary dysmenorrhea in ginger. | VAS | Mean age 21 years, 78 female students with moderate to severe dysmenorrhea | Placebo | 500 mg ginger TID in first 3 days of menstruation | triple-blind, randomized, placebo controlled trial | Rahnema | 19 | |||||||||
| 5 | Two patients were excluded due to nausea | Pain severity in | VAS | 60 students | Placebo |
| A clinical trial before-after 2 cycles | Delaram | 56 | |||||||||
| 5 | Uncomplicated | In both Mefenamic acid and | Questionnaire and VAS | 80 single female students 20-30 years old who experienced |
| triple-blind randomized cross over clinical trial | Modaress | 28 | ||||||||||
| Cannot be calculated | Uncomplicated | Among consumer groups | VMSS | 100 students 14-18 years old | 5 groups: three groups consumed | Randomized clinical trial 3 cycles | Tavasoli | 22 | ||||||||||
| Cannot be calculated | Not mentioned | Pain during the first 3 days of treatment cycles compared with cycles without treatment significantly reduced. | Questionnaire | 70 students with moderate dysmenorrhea | 1 capsule of | Randomized clinical trial | Satar-zadeh | 59 | ||||||||||
| Cannot be calculated | Uncomplicated | After consumption | VAS and VMSS | 50 single female students 18-25 years old | 10 g of infused plant powder TID (2 days before and 3 days after the onset of pain) | Clinical trial, 3 cycles | Olfati | 41 | ||||||||||